Tuesday, 13 April 2021

Green Cross begins clinical trials for hepatitis drug

13 July 2015 | News | By BioSpectrum Bureau

Green Cross begins clinical trials for hepatitis drug

The drug is developed through recombinant gene technology

The drug is developed through recombinant gene technology

Singapore: South Korean biopharmaceutical company, Green Cross recently announced that it has received approval from the Ministry of Food and Drug Safety (MFDS) for its phase I clinical trial plan for "Hepabig-gene", a recombinant gene therapy, for treatment of the chronic hepatitis B virus (HBV).

Hepabig-gene has a potential to reduce HBV infection in liver transplant patients. The company had carried out clinical studies to evaluate the safety and efficacy of the Hepabig-gene on liver transplant patients who had underlying medical conditions of HBV infection.

According to Green Cross, the product has higher purity levels than existing plasma-based products and is more capable of neutralizing HBV. Therefore smaller doses are required over a shorter period compared with previous plasma-based products.

An official from the Green Cross said, "Until now, no country or company in the world has succeeded in the commercialization of a gene recombinant hepatitis B antibody treatment. So, Hepabig-gene is highly likely to be the world's first gene recombinant hepatitis B antibiotic medicine, if it is proven safe and effective."

Nearly 350 million people worldwide are suffering from HBV infection. Chronic hepatitis B patients are at considerably at a higher risk for the development of cirrhosis and hepatocellular carcinoma. Liver transplants are the only treatment option for such patients.

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account